Yuhan Licenses Out Degenerative Disc Therapy To Spine Despite Earlier Trial Failure

 
• By Jung Won Shin

South Korean pharma firm licenses out to US venture Spine Biopharma novel peptide drug for degenerative disc disease YH14618, despite a Phase II failure and trial halt in 2016.

3D spinal cord
YUHAN'S DISC DISEASE CANDIDATE LICENSED TO SPINE • Source: Shutterstock

More from South Korea

More from Focus On Asia